Fox Run Management L.L.C. bought a new position in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 2,953 shares of the biopharmaceutical company’s stock, valued at approximately $1,110,000.
Several other institutional investors and hedge funds have also recently bought and sold shares of the company. Westpac Banking Corp grew its holdings in shares of Regeneron Pharmaceuticals by 5.9% in the 4th quarter. Westpac Banking Corp now owns 17,956 shares of the biopharmaceutical company’s stock worth $6,751,000 after purchasing an additional 1,000 shares during the last quarter. Schwab Charles Investment Management Inc. grew its holdings in shares of Regeneron Pharmaceuticals by 5.9% in the 4th quarter. Schwab Charles Investment Management Inc. now owns 284,567 shares of the biopharmaceutical company’s stock worth $106,986,000 after purchasing an additional 15,924 shares during the last quarter. National Pension Service grew its holdings in shares of Regeneron Pharmaceuticals by 4.0% in the 4th quarter. National Pension Service now owns 72,009 shares of the biopharmaceutical company’s stock worth $27,073,000 after purchasing an additional 2,763 shares during the last quarter. Bank of Montreal Can grew its holdings in shares of Regeneron Pharmaceuticals by 342.4% in the 4th quarter. Bank of Montreal Can now owns 188,828 shares of the biopharmaceutical company’s stock worth $70,991,000 after purchasing an additional 146,147 shares during the last quarter. Finally, Atria Investments LLC grew its holdings in shares of Regeneron Pharmaceuticals by 50.4% in the 4th quarter. Atria Investments LLC now owns 1,930 shares of the biopharmaceutical company’s stock worth $726,000 after purchasing an additional 647 shares during the last quarter. 66.63% of the stock is currently owned by institutional investors and hedge funds.
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) opened at $371.28 on Friday. The company has a current ratio of 3.63, a quick ratio of 3.07 and a debt-to-equity ratio of 0.12. Regeneron Pharmaceuticals Inc has a 52-week low of $340.09 and a 52-week high of $543.55. The stock has a market cap of $39,890.00, a PE ratio of 33.72, a price-to-earnings-growth ratio of 1.42 and a beta of 1.52.
Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Wednesday, November 8th. The biopharmaceutical company reported $3.99 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.83 by $0.16. Regeneron Pharmaceuticals had a net margin of 23.17% and a return on equity of 25.73%. The company had revenue of $1.50 billion for the quarter, compared to the consensus estimate of $1.45 billion. During the same period in the prior year, the company posted $3.13 EPS. The company’s revenue was up 23.0% compared to the same quarter last year. equities research analysts anticipate that Regeneron Pharmaceuticals Inc will post 13.55 earnings per share for the current year.
Several equities research analysts have recently weighed in on the stock. BTIG Research reaffirmed a “buy” rating and issued a $520.00 target price on shares of Regeneron Pharmaceuticals in a report on Wednesday, November 22nd. BMO Capital Markets set a $444.00 target price on shares of Regeneron Pharmaceuticals and gave the stock a “hold” rating in a report on Monday, November 27th. Citigroup lowered shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $480.00 to $380.00 in a report on Friday, December 1st. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $540.00 target price on shares of Regeneron Pharmaceuticals in a report on Monday, November 13th. Finally, JPMorgan Chase & Co. reiterated a “hold” rating on shares of Regeneron Pharmaceuticals in a research report on Tuesday, November 28th. Two equities research analysts have rated the stock with a sell rating, fifteen have given a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $471.11.
COPYRIGHT VIOLATION WARNING: This news story was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this news story on another domain, it was illegally stolen and republished in violation of international copyright laws. The legal version of this news story can be read at https://www.dispatchtribunal.com/2018/01/19/fox-run-management-l-l-c-buys-shares-of-2953-regeneron-pharmaceuticals-inc-regn.html.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.